Companies › TransThera Sciences (Nanjing)
2 active drug programs in 5 registered trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TT-00420 (tinengotinib) Fibroblast growth factor receptor (FGFR) inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 3 | Cholangiocarcinoma; Cholangiocarcinoma Metastatic; Breast Cancer; Prostate Cancer (CRPC) | Dec 2026 |
| TT-01488 non-covalent reversible BTK inhibitor | BTK | Phase 1 | B-Cell Malignancies | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06057571 | TT-00420 (tinengotinib) | Phase 2 | Cholangiocarcinoma Metastatic | Oncology | Jul 2025 |
| NCT05948475 | TT-00420 (tinengotinib) | Phase 3 | Cholangiocarcinoma | Oncology | Dec 2026 |
| NCT07498478 | TT-00420 (tinengotinib) | Phase 2 | Breast Cancer | Oncology | Jun 2027 |
| NCT05683717 | TT-01488 | Phase 1 | B-Cell Malignancies | Oncology | Oct 2028 |
| NCT07871110 | TT-00420 (tinengotinib) | Phase 2 | Prostate Cancer (CRPC) | Oncology | Dec 2028 |
Tyra Biosciences Johnson & Johnson (Janssen) AstraZeneca Taiho Oncology Exelixis QED Therapeutics, a BridgeBio company Hutchmed Eisai BeOne Medicines Eli Lilly
Elevar Therapeutics NOBO Medicine Nurix Therapeutics Clarity Pharmaceuticals TYK Medicines
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.